Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Gastro-News
Erschienen in: Gastro-News 4/2019

05.08.2019 | Chronisch-entzündliche Darmerkrankungen | fortbildung

Hepatologie — Teil 4: Cholestatische Lebererkrankungen

Verbesserte Prognose, aber limitierte Therapieoptionen für PBC und PSC

verfasst von: Dr. med. Maria Teresa Koenen, Dr. med. Henning W. Zimmermann, Prof. Dr. med. Christian Trautwein

Erschienen in: Gastro-News | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Krankheitsbild cholestatischer Lebererkrankungen umfasst ein weites Spektrum an Diagnosen. Ursächlich können immunologische, infektiöse, genetische und toxische Mechanismen sein. Die große Spannbreite möglicher Ätiologien erfordert eine detaillierte Anamneseerhebung, körperliche Untersuchung, laborchemische und apparative Abklärung.
Literatur
1.
Tang R, Chen H, Miao Q et al. The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. Genes and immunity 2015; 16: 193–198CrossRef
2.
Bianchi I, Carbone M, Lleo A et al. Genetics and epigenetics of primary biliary cirrhosis. Seminars in liver disease 2014; 34: 255–264CrossRef
3.
4.
Strassburg CP et al. S2k Leitlinie Autoimmune Lebererkrankungen, AWMF-Reg. Nr. 021-27, Gastroenterol 2017; 55: 1135–1226
5.
Kremer AE, Feramisco J, Reeh PW et al. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochim Biophys Acta 2014; 1842: 869–892CrossRef
6.
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194: 293–299CrossRef
7.
Lammert C, Nguyen DL, Juran BD et al. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2013; 45: 589–594CrossRef
8.
Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Seminars in liver disease 2014; 34: 352–360CrossRef
9.
Heathcote J. The clinical expression of primary biliary cirrhosis. Seminars in liver disease 1997; 17: 23–33CrossRef
10.
Menon KV, Angulo P, Weston S et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. Journal of hepatology 2001; 35: 316–323CrossRef
11.
Pares A, Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008; 12: 407–424CrossRef
12.
Berg PA, Klein R, Lindenborn-Fotinos J et al. ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet 1982; 2: 1423–1426CrossRef
13.
Gershwin ME, Mackay IR, Sturgess A et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525–3531PubMed
14.
Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmunity reviews 2014; 13: 441–444CrossRef
15.
Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert review of clinical immunology 2014; 10: 1667–1678CrossRef
16.
Corpechot C, Wendum D. Primary biliary cirrhosis: is there still a place for histological evaluation? Clin Res Hepatol Gastroenterol 2013; 37: 556–558CrossRef
17.
Nakanuma Y. Primary biliary cirrhosis: is there still a place for histological evaluation?. Clin Res Hepatol Gastroenterol 2014; 38: e1–e2CrossRef
18.
Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Archiv A, Pathological anatomy and histology 1978; 379: 103–112CrossRef
19.
Scheuer PJ. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J 1983; 59: 106–115CrossRef
20.
Hiramatsu K, Aoyama H, Zen Y et al. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology 2006; 49: 466–478CrossRef
21.
Poupon RE, Chretien Y, Poupon R et al. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17: 599–604CrossRef
22.
Poupon RE, Lindor KD, Cauch-Dudek K et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884–890CrossRef
23.
Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715–720CrossRef
24.
Kuiper EM, Hansen BE, de Vries RA et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281–1287CrossRef
25.
Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. Journal of hepatology 2011; 55: 1361–1367CrossRef
26.
Lammers WJ, van Buuren HR, Hirschfield GM et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338–1349 e5; quiz e15CrossRef
27.
28.
Hirschfield GM, Mason A, Luketic V et al. Efficacy of obeticholic Acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic Acid. Gastroenterology 2015; 148: 751–761 e8CrossRef
29.
Nevens F, Andreone P, Mazzella G et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England journal of medicine 2016; 375: 631–643CrossRef
30.
Corpechot Ch, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain Ch, Abergel A, Debette-Gratien M, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis N Engl. J Med 2018; 378: 2171–2181
31.
Trauner M, Halilbasic E, Kazemi-Shirazi L et al. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis 2014; 32: 631–636CrossRef
32.
Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000; 14: 33–40CrossRef
33.
Tandon P, Rowe BH, Vandermeer B et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102: 1528–1536. Epub 2007 Mar 31CrossRef
34.
Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. The American journal of gastroenterology 2003; 98: 2736–2741CrossRef
35.
Pells G, Mells GF, Carbone M et al. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. Journal of hepatology 2013; 59: 67–73CrossRef
36.
37.
Boberg KM, Chapman RW, Hirschfield GM et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374–385CrossRef
38.
Corpechot C, Carrat F, Poujol-Robert A et al. Noninvasive elastographybased assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198–208CrossRef
39.
Pang JX, Zimmer S, Niu S et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PloS one 2014; 9: e95776CrossRef
40.
Singh S, Fujii LL, Murad MH et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2013; 11: 1573–1584.e1— 2; quiz e88—9CrossRef
41.
Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364–1369CrossRef
42.
Tischendorf JJ, Hecker H, Kruger M et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. The American journal of gastroenterology 2007; 102: 107–114CrossRef
43.
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237–267CrossRef
44.
Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181–1188CrossRef
45.
Boonstra K, Weersma RK,van Erpecum KJ et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045–2055CrossRef
46.
Weismuller TJ, Trivedi PJ, Bergquist A et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 2017; 152: 1975–1984CrossRef
47.
Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Seminars in liver disease 1991; 11: 31–39CrossRef
48.
Loftus EV Jr, Harewood GC, Loftus CG et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91–96CrossRef
49.
Benito de Valle M, Rahman M, Lindkvist B et al. Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clinical gastroenterology and hepatology: the official clinicalpractice journal of the American Gastroenterological Association 2012; 10: 769–775 e2CrossRef
50.
Bjornsson E, Chari S, Silveira M et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011; 18: 198–205CrossRef
51.
Bjornsson E, Boberg KM, Cullen S et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51: 731–735CrossRef
52.
Naess S, Bjornsson E, Anmarkrud JA et al. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver international: official journal of the International Association for the Study of the Liver 2014; 34: 1488–1495CrossRef
53.
54.
Claessen MM, Lutgens MW, van Buuren HR et al. More right-sided IBDassociated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331–1336CrossRef
55.
Hirschfield GM, Karlsen TH, Lindor KD et al. Primary sclerosing cholangitis. Lancet 2013; 382: 1587–1599CrossRef
56.
Lindstrom L, Hultcrantz R, Boberg KM et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2013; 11: 841–846CrossRef
57.
Eaton JE, Silveira MG, Pardi DS et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. The Americanjournal of gastroenterology 2011; 106: 1638–1645
58.
Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003; 38: 991–995CrossRef
59.
Talwalkar JA, Angulo P, Keach JC et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. The American journal of gastroenterology 2005; 100: 308–312CrossRef
60.
Talwalkar JA, Gossard AA, Keach JC et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver international: official journal of the International Association for the Study of the Liver 2007; 27: 451–453CrossRef
61.
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017; 76(3): 549–558CrossRef
62.
Tabibian JH, Weeding E, Jorgensen RA et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis — a pilot study. Aliment Pharmacol Ther 2013; 37: 604–612CrossRef
63.
Gotthardt DN, Rudolph G, Kloters-Plachky P et al. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointestinal endoscopy 2010; 71: 527–534CrossRef
64.
Siddiqui UD, Banerjee S, Barth B et al. Tools for endoscopic stricture dilation. Gastrointestinal endoscopy 2013; 78: 391–404CrossRef
65.
Ponsioen CY, Arnelo U, Bergquist A, Rauws EA, Paulsen V, Cantú P, Parzanese I, De Vries EM, van Munster KN, Said K, Chazouillères O, Desaint B, Kemgang A, Färkkilä M, Van der Merwe S, Van Steenbergen W, Marschall HU, Stotzer PO, Thorburn D, Pereira SP, Aabakken L No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology 2018; 155(3): 752–759CrossRef
66.
Claessen MM, Vleggaar FP, Tytgat KM et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158–164CrossRef
67.
Levy C, Lymp J, Angulo P et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Digestive diseases and sciences 2005; 50: 1734–1740CrossRef
Metadaten
Titel
Hepatologie — Teil 4: Cholestatische Lebererkrankungen
Verbesserte Prognose, aber limitierte Therapieoptionen für PBC und PSC
verfasst von
Dr. med. Maria Teresa Koenen
Dr. med. Henning W. Zimmermann
Prof. Dr. med. Christian Trautwein
Publikationsdatum
05.08.2019
Verlag
Springer Medizin
Erschienen in
Gastro-News / Ausgabe 4/2019
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI
https://doi.org/10.1007/s15036-019-0633-1

Weitere Artikel der Ausgabe 4/2019

Gastro-News 4/2019 Zur Ausgabe

der besondere fall

Harnverhalt mit ungewöhnlicher Ursache

infopharm

Signifikante Vorteile für Integrin-Antagonisten

infopharm

Alginat als wirksame Alternative zur PPI-Einnahme

journal club

Postoperative Komplikationen bei Morbus-Crohn-Patienten unter TNFα-Blockern

journal club

Langfristige Folgen einer Antibiotika-Therapie im Säuglingsalter

editorial

Nachsorge mit Maß

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Bildnachweise